initi coverag
near-term spinraza risk loom long-term platform attract initi neutral
initi coverag neutral rate pt ioni
rna-platform compani produc one largest pipelin
biotech clinic asset share ytd vs
think reflect high investor expect base busi pipelin
think near-term competit headwind spinraza ioni singl largest revenu
driver reflect current valuat see growth potenti
neurolog pipelin huntington al view high risk
competit space
think competit especi oral sma product risdiplam pose
underappreci risk lead product spinraza spinraza royalti current
roughli half ioni revenu data type sma patient upcom medic
meet cure sma major event sma space
think investor begin fulli appreci risk spinraza oral product
vs spinraza intens spinal inject think risdiplam truli
disrupt potenti spinraza sale potenti launch
consensu
view huntington high risk program could take longer
expect show cognit benefit investor hope see huntington
diseas hd larg opportun updat potenti cognit data
faster expect regulatori path could drive upsid focus
updat ole studi cours year hdsa
possibl other particularli focus whether link cognit
improv seen howev think program risk
competit appreci think ionis/roch success mani
competitor could limit ultim upsid wave nc
proof concept data hd uniqur qure piro ow
enter clinic gene therapi
cautiou near term tegsedi number think competit
alnylam young ow particularli toler could affect long-term
adher uptak forecast vs factset consensu
vs think popul take time diagnos
bring care key swing factor launch initi think
tegsedi profil subq could incentiv uptak vs alnylam onpattro
iv could potenti upsid number
disclosur section may found page
initi coverag ioni
power platform technolog cautiou near-term around
competit core sma franchis
ioni ioni neutral pt see long term potenti pipelin near-
term headwind sma
ioni platform technolog compani base antisens rna approach
compani power drug discoveri engin asset clinic
ioni asset clinic develop approved/l stage asset includ
think ioni platform signific potenti long term near term
cautiou around competit threat lead revenu driver spinraza
long term think ttr market especi next-gener
program could larger investor appreci howev near-term
see mani unknown around tegsedi launch key stock focu
see growth potenti neurolog program develop
huntington al view high risk competit space
thought month outlook
appreci risk lead product spinraza spinraza royalti partner
young neutral current roughli half ioni revenu think data
updat regulatori progress risdiplam gene therapi
beyond could draw greater investor attent competit pressur
potenti cognit benefit hd data could drive upsid
howev view high risk program could take longer
expect show cognit benefit investor hope see
huntington diseas hd larg opportun updat potenti
cognit data faster expect regulatori path could drive upsid
howev think program risk competit
slightli street tegsedi estim think
competit complex pathway bring patient treatment could
limit initi uptak patient us diagnos think
alnylam may taken meaning share patient far
therefor think rate could slower find next wave diagnos
patient think tegsedi side effect profil could also limit uptak rel
event watch
competit updat sma competitor program novarti
cover roch cover /ptct young overweight
cure sma confer
data updat huntington program partner roch
hdsa potenti confer
potenti color regulatori path huntington roch
late earli
tegsedi quarterli sale color product launch
waylivra product launch eu addit phase data
short interest float
day cover short
upsid current market price
compani report factset research cantor fitzgerald research
total
tabl content roadmap think key understand current valuat
thesi point think pipelin potenti fairli valu given risk lead
share year date vs think investor high expect base busi pipelin
key program see drive valuat next month spinraza huntington tegsedi al
valuat work analysi key asset see downsid current level sale clinic program live investor look
report took detail look program see near-term competit risk spinraza fulli appreci investor think
data clinic endpoint cognit need credit huntington assign
think near-term competit headwind spinraza ioni singl largest revenu driver reflect current valuat data type sma patient
upcom medic meet cure sma major event sma space think investor begin fulli appreci risk spinraza
consensu model spinraza growth continu come year
lower consensu respect base case spinraza estim reflect elli merl model biogen
spinraza estim young pleas refer publish research model
see key risk competitor notabl oral product risdiplam key longer term data updat regulatori file
huntington program partner roch greatest upsid risk neutral thesi howev think high risk program could take
longer expect show cognit benefit investor hope see
think hd program signific potenti preval sma
howev mani earlier stage competitor horizon us suggest ionis/roch success mani competitor could limit
ultim upsid wave nc proof concept data hd uniqur qure piro overweight enter clinic gene
therapi
expect get data updat on-going open label extens ole studi investor focus see cognit benefit
cautiou near-term tegsedi number due competit alnylam young ow particularli toler think affect long term
forecast vs consensu vs consensu factset
think popul take time diagnosi bring care key swing factor launch
initi think tegsedi profil subq could incentiv uptak vs alnylam onpattro iv view potenti upsid number
longer term think ttr-lrx next gener program could drive signific growth due significantli improv safeti profil potenti
expand broader popul although also next gener develop well
think rna-bas therapeut ioni antisens class signific potenti long-term strateg target select key success
ioni leader antisens technolog potenti key player growth novel therapeut modal
howev note grow competit genet medicin space
ioni strategi clinic develop uniqu mani program out-licens
gener signific cash flow compani diversifi risk across program
ioni receiv meaning cash flow larger biotech pharma partner
ioni one profit mid-cap biotechnolog compani result signific
revenu partner
downsid howev compani receiv less econom success product
result partnership strategi ioni one largest clinic preclin
pipelin biotech base antisens platform technolog
ioni antisens technolog power platform technolog use treat
underli caus mani diseas target rna
diseas caus specif protein
tradit drug small molecul antibodi target exist protein improv diseas
antisens technolog target mrna translat protein
think recent chemic enhanc lica alni galnac help make rna-
platform suitabl rare diseas also chronic usag larger popul
howev grow competit genet medicin space rna
player well gene therapy/edit
ioni key compani pioneer develop rna base therapeut
howev compani face competit genet medicin compani alnylam
addit advanc gene therapi gene edit technolog think make strateg
target select critic long term success
companyapproachionisantisensealnylamrnaisareptapmo/ppmomodernamrnaakceaantisensearrowheadrnaiwavestereopur oligonucleotidedicernagalxc rnaiproqrrna therapeuticstransl biomrnaarbutusrnai/rnai triggerexicuresnaarcturuslunar lipid deliveri rna medicinesregulusmicrornaphiopharmarnaisourc compani data mani asset key program think could drive ioni valuat next
month spinraza tegsedi huntington
matter
could larg
opportun key updat
come
cautious optimist see high
earlier competitor program similar
target think could limit ultim reward
cognit data hdsa june
see potenti program long-term
path market could take longer riskier
potenti updat addit medic
meet september- octob
think bake expect
current royalti
near-term
think competit risk gene therapi
especi roche/ptc risdiplam
sma gene therapi initi approv may
risdiplam data file updat
cautiou near-term launch estim
due complex diagnosi due
favor toler profil compet product
near term see competit catalyst could increas investor concern competit
threat ions/biib spinraza
think american academi neurolog meet may could provid potenti downsid
spinraza thesi summar along key risk debat
sma genet disord affect central nervou system muscl current
preval roughli us spinraza current approv ww market
receiv royalti around
think near-term competit headwind spinraza ioni singl largest revenu
driver reflect current valuat data type sma patient
upcom medic meet cure sma major event sma space
think investor begin fulli appreci risk spinraza
roche/ptc risdiplam oral develop type sma
novarti zolgensma gene therapi develop type sma
american neurolog meet may expect ptc/rog nv type
data
may potenti approv zolgensma key watch broad label
cure sma medic mtg june juli could get competit updat
expect file fda accept risdiplam
world muscl societi medic mtg oct could get data
risdiplam sunfish type pivot data ye earli
risdiplam firefish type pivot data
combin usag new therapi includ spinraza
novarti roche/ptc approv broader label type type
data read
launch approv timelin competit expect roch
cantor fitzgerald compani report
biomark data look interest huntington look impact cognit
effect time
huntington diseas hd thesi summar along key risk debat
hd larg preval fatal diseas treatment think potenti even larger
product spinraza preval sma program partner roch ioni receiv royalti
low teen
think demonstr cognit benefit clinic trial set challeng slower progress diseas
think full phase may need file estim readout think success
like earlier player may well think limit ultim upsid clinic success near-
term stock perspect
phase top-line data
uniqur gene therapi studi begin
earli may pk/pd present potenti updat biomark data
hdsa late june data updat ole
competitor top line data
and/or potenti data updat ole eha md
late potenti color regulatori path forward hd
demonstr cognit benefit ole studi
level cognit benefit get regul potenti comfort acceler file strategi
potenti file
role lower wild-typ htt protein addit mutant htt protein much mutant htt
need lower see clinic meaning benefit
brain penetr exposur need deeper part brain see clinic benefit
cantor fitzgerald compani report
lower street expect tegsedi near-term compani
develop next gener lica assum greater long-term sale
model next gener lica akcea-ttr-lrx launch
tegsedi thesi summar along key risk debat
tegsedi fulli own akcea nc tegsedi approv ww
polyneuropathi caus hereditari transthyretin mediat
amyloidosi hattr diseas caus genet mutat lead
progress neuropath impair mutat cardiac
cautiou around near-term launch think ttr
market could larger next gener product think
could take greater share long-term
alnylam onpattro approv polyneuropathi
chen ow tafamidis- file cardiomyopathi come
frequent discuss competit due cardiac neuropath
quarterli updat
juli us approv date tafamidi cardiomyopathi wild type
phase studi initi akcea-ttr-lx polyneuropathi
cardiomyopathi wild type
investor assum alnylam take major market due
perceiv better efficaci toler
tegsedi conveni onpattro sinc weekli subq
though monitor requir question whether conveni might
tafamidi market cardiomyopathi lower market
opportun alnylam ions/akca
cantor fitzgerald compani report
view competitor sma updat hd program updat tegsedi launch
trend key stock move event
ioni mani clinic program underway expect signific news flow across mani program
updat greatest stock sensit investor focu view
ioni programwhatwhen data first cohort confer may present potenti updat biomark safeti data ole confer may olehdsa june proof concept data congress septemb eha confer octob huntington smaroch investor call datamay novarti us sma gene therapi pdufa label mayroche/ptc risdiplam data updat type type confer may sma type data updat first type data confer may june octob tegsediquarterli salesquarterlysourc compani datahuntington ssmapotenti updat olepotenti updat competitor wvepotenti sma competitor updat detail catalyst sma competitor data updat earli may potenti
cognit data huntington program late june tegsedi launch trend focu
assetdiseasepartnercatalyst/whatwhenstock importancetegsedi inotersen ttr amyloidosisakceacommerci updatesquarterli updat novarti sma us pdufa may time-frame spinrazasmabiogencompetitor updat novarti sma type data updat may phase top line dec may hd rochepk/pd present potenti updat data ole safeti biomark mhtt lower may part et spinrazahd smabiogen rocheroch investor call discuss data updatespotenti discuss risdiplam spinraza competitor well htt program partner may competitor data ole data updat hdsa convent june et spinrazasmabiogencompetitor updat curesma conferencejun ttr amylodosisakceacompetitor updat tafamidi pfizer pdufajuli phase broaden top line datamid data healthiesmid neck cancerastrazenecaphas final data inform azn go/no go decis mid end stage renal diseasebayerphas studi datamid launch euquarterli compani data cantor fitzgerald equiti catalyst estim initi data esmo webcast neurolog pipelin webcast platform advanc catalyst potenti hd data color around file path tegsedi launch
updat risdiplam data matur move closer market
assetdiseasepartnercatalyst/whatwhenstock importancetegsedi inotersen ttr amyloidosisakceacommerci updatesquarterli launch euquarterli updat risdiplam roche/ptc filingplan akcea-apo -lrxcardiovasuclar diseaseakceaphas init studi design detail attrttr polyneuropathayakceaphas studi intiat attrttr wild type cardiomyopathyakceaphas studi intiat phase decis phase fibrosisn/aphas thalassemian/aphas wild type year data updat benson studi wild-typ hereditari trial updat re-fil process updat olepotenti updat competitor wvemd congress septemb spinrazasmabiogenpotenti sma competitor updat octob updat olepotenti updat competitor wveeha confer octob regulatori ionis-httrx huntington srochepotenti regulatori filingl plan discuss ole data regul explor faster file strategysourc compani data cantor fitzgerald equiti catalyst estim plan meet regul next cohort complet valuat base valuat analysi think current level fairli reflect credit
number pipelin program risk-adjust basi
programpartnerprob successdcf valuationttr-lrx wild type fc us fc eu fpl us fpl ex-u approv compani data cantor fitzgerald equiti research estim valuat use probabl adjust dcf valu ioni ioni npv valu
beyond give platform technolog credit
extend estim assign termin growth rate account continu
gener clinic asset platform technolog
beyond free cash flow base case valuat
termin valu beyond worth base case valuat
cantor biotech ioni dcf valuationelli tax non-control interest base work free cash present valu sharestermin growth termin non-control interest share per per cantor fitzgerald research risk thesi
limit competit risk key commerci asset includ spinraza tegsedi
robust clinic data roche/ion huntington program current late stage develop
favor proof concept data readout reflect base case
new high valu collabor larg pharmaceut partner provid valid platform
faster clinic develop earli late stage program new platform technolog lica
greater expect competit risk key commerci asset includ spinraza tegsedi
worst expect clinic data roche/ion huntington program current late stage develop
earli stage clinic setback either safeti efficaci
clinic efficaci setback new platform technolog lica
sma think commerci uncertainti market
key competitor come underappreci
updat competitor novarti gene therapi roche/ptc oral
product could increas focu near-term commerci headwind
spinal muscular atrophi sma life-threaten neuro-muscular disord affect
grow patient us alon
sma untreat fatal genet neuromuscular disord
differ type sma type sever
estim current preval us world-wide expect number
grow significantli time emerg better treatment
spinraza revolution live thousand patient sma current sale run-
rate close
spinraza approv decemb patient therapi
world-wide
spinraza efficaci life-chang sma patient particularli type
spinraza dose intrathec inject inject spine dose everi month
think zolgensma risdiplam could significantli chang sma treatment landscap
time present uncertainti around valu spinraza long-term revenu stream
think roche/ptc oral risdiplam potenti directli compet take share spinraza
type patient
type sma think gene therapi data look much stronger data spinraza
think combin usag least initi spinraza could limit sale impact
broader label type well type sma could lead pressur sale
programcompanyu approv estimate eu approv estimate spinrazabiogen/ ioni decemb commentari us file accept dec roch plan file ye compani data cantor fitzgerald equiti research think investor forecast spinraza could chang dramat next month
learn competitor data non-typ get initi commerci data
valu spinraza long term revenu stream model spinraza sale vs
see potenti disrupt risdiplam gene therapi
think hard understand actual commerci impact see first commerci
experi gene therapi data risdiplam certainli think risk real
spinraza estim reflect elli merl model biogen spinraza estim young pleas refer
publish research model
report take detail look sma market assess potenti market impact
new competitor think spinraza usag evolv
product compar efficaci safeti
take type think risdiplam gene therapi data look better vs spinraza
seen much less data type competitor base type result think type result gene therapi
risdiplam could continu look favor spinraza
updat year key elucid type competit threat spinraza
first gene therapi type data
longer term updat risdiplam non type sunfish import assess risdiplam efficaci popul
think like pose meaning competit threat spinraza
gene therapi and/or risdiplam work sma type type initi label broad
take expect product show strong data type patient base data far type
think product receiv broad label initi look close data
much combin usag agent
think gene therapi depend payer could use combin spinraza risdiplam think combin
spinraza risdiplam would make littl mechanist sens
think oral would prefer mainten regimen
larg sma market grow
mani patient larg type still untreat think conveni option grow market less sever patient
physician say
strong prefer excit gene therapi
excit prospect oral wait data
spinraza much long term data patient experi think real safeti risk addit qualiti life intrathec
inject may counter familiar benefit physician check
efficaci comparison emerg data profil gene therapi risdiplam look
strong compar spinraza type
far seen limit type data none gene therapi risdiplam
howev expect get much type data think help understand
role agent play
review type data initi type data case risdiplam think
type data like type data product highli competit spinraza
risdiplam product think greatest disrupt potenti spinraza type
data look expect updat key stock focu
data far think zolgensma risdiplam could superior efficaci spinraza
greater bodi long-term data spinraza data treatment year
think emerg data profil zolgensma gene therapi risdiplam oral look competit
far primarili data type patient compar would expect data
look superior type patient benefit could also carri type patient
inspinrazaendear naturalhistoryspinraza type event free surviv month comparison key motor mileston data type sma patient suggest data
far gene therapi risdiplam could improv spinraza efficaci
obtain day
therapi
least mo longer
firefish studi exposur
treatment
measur day
measur month
increas point chop-intend mo point mo therapi
note number patient avexi studi spinraza confer detail may impact studi unknown
type gene therapi show event free surviv rate vs spinraza year
think remark improv though limit cross-trial comp
gene therapi show remark improv event-fre surviv motor function
sma type gene therapi strong efficaci suggest approv vast major type
sma babi least get treat gene therapi potenti also spinraza
event free surviv sma type left vs spinraza right
much less known competitor data profil type larger market
opportun risk spinraza data may key updat type
particular expect get data zolgensma type patient first time
addit sunfish data updat offer greater clariti risdiplam efficaci non type
base review type dataset risdiplam non-typ data far think data
updat compar favor spinraza type sma
think key updat spinraza franchis think type
greatest revenu risk competitor could long term
type compani data cantor fitzgerald equiti research base zolgensma data type expect see strong efficaci first
present type data expect includ nv regulatori file
seen impress data zolgensma type sma yet seen data
see zolgensma efficaci profil type sma think import
understand commerci potenti larger patient popul
continu updat risdiplam sunfish type studi import
assess product threat spinraza larger patient popul
focus updat sunfish studi risdiplam
comparison motor function score non-typ sma suggest us least equival
efficaci risdiplam vs spinraza rel limit data far
data cherish phase trial
mo treatment
preliminari data sunfish part
trial risdiplam treat sma type
patient mo treatment
proport respond
respond point increas baselin
respond point increas baselin
proport respond non type patient appear equival potenti stronger
due use differ motor function scale comparison treat caution
sunfish data releas far somewhat limit updat cure
sma world muscl help understand profil
advantag broader tissu distribut vs simpli distribut
smn express ubiquitous-
non-cn role smn
glucos metabol pancreat develop defect report sma patient pre-clin
model demonstr due non-cn role
pre-clin studi suggest smn protein requir normal liver
pre-clin model demonstr critic role protein regul muscl
significantli muscl atrophi hallmark sma
drug potenti target non-cn smn defect
spinraza target non-cn smn defect due intrathec administr
 inject patient rectifi non-cn smn non-divid cell divid cell
episom dna element rapidli lost
risdiplam due oral administr rout target smn outsid well
larg bodi competitor data year could begin illustr
firefish part result motor function babi type sma
updat sunfish part safeti toler pk/pd dose-
find studi includ exploratori efficaci data patient type
spinal muscular atrophi sma treat risdiplam
firefish part surviv ventil swallow abil babi type
earli diagnosi speed effect spinal muscular atrophi type
event-fre surviv motor mileston achiev follow
nusinersen intervent contrast natur histori type spinal muscular
gene-replac therapi grt spinal muscular atrophi type
long-term follow- phase clinic trial
number need treat nnt spinal muscular atrophi type
rel nusinersen
gene- replac therapi grt presymptomat spinal muscular
gene- replac therapi grt spinal muscular atrophi type
phase studi intrathec administr gene-replac
therapi grt spinal muscular atrophi type strong
gene replac therapi spinal muscular atrophi type improv
surviv pulmonari nutrit support motor function decreas
spinraza chronic intrathec inject intens commit check suggest
could lead patient switch risdiplam even risdiplam less activ
intrathec deliveri allow therapeut cross blood brain barrier procedur highli
intens carri long term risk well spinraza dose everi month
damag neurolog tissu
risk local infect deep tissu infect potenti fatal mening
anesthesia routin use reduc patient discomfort increas concern
impact repeat anesthesia exposur develop nervou system infant
involv fluoroscopi base imag expos patient repeat radiat
thu spinraza long-term data profil current better understood versu newer therapi
think physician weigh risk intrathec procedur outsid impact
procedur qualiti life
mani sma diagnos patient remain untreat particularli type adult patient
segment think alreadi demonstr reluct toward intrathec inject
biogen spinraza treat patient vs preval
largest growth spinraza current come type adult patient
deploy larger salesforc particularli focu adult popul
still remain potenti growth near term due dynam
hand think slower uptak older patient set could suggest
willing switch oral one-tim intrathec vs chronic
exhibit roch recent estim sma diagnos populationsourc roch spinraza estim versu consensu consensu result forecast
patient switch competitor product risdiplam
spinraza estim reflect elli merl model biogen spinraza estim young pleas refer
publish research model
huntington diseas could major
growth driver ioni
could first disease-modifi agent approv hd
updat signific stock move potenti
howev conserv given complex potenti
competitor space
take hd could signific opportun ioni howev mani clinic unknown
earli stage competitor leav us cautious optimist key updat
signific preval unmet need roch ioni program farthest ahead develop
seriou fatal indic preval spinraza sma
data updat see signific upsid
see strong cognit data on-going ole studi potenti updat throughout
color roch suggest faster path market roch discuss potenti acceler file
regul toward end
mani earli stage competitor success think highli like mani
earlier competitor think limit upsid potenti longer term
ionis/roch lead mani approach close follow coattail similar
expect proof concept data wve allel specif approach
uniqur gene therapi approach enter clinic
mani clinic unknown add develop challeng mani outstand clinic question think
make challeng area drug develop
question around much protein knockdown necessari long take show cognit
improv long-term safeti implic wild-typ knockdown key
huntington diseas hd progress fatal neurodegen diseas typic
present adulthood
larg preval approxim symptomat hd patient us anoth
approxim peopl carri mutat practic guarante develop hd
time
eventu fatal diseas modifi therapi treatment slow diseas
progress diseas ultim fatal approxim year initi symptom onset
progress loss cognit physic function hd build-up mutant huntingtin protein
mhtt lead progress cognit impair loss physic control time lead
lengthi progress diseas cours underscor high unmet need diseas modifi
therapi symptomat asymptomat patient
mani patient know decad ahead symptom onset carrier gene go
develop diseas
sadli high rate suicid know go begin develop
diseas underscor high unmet need
hd caus toxic gain function one allel lead accumul mutant
huntingtin protein mhtt time
hd inherit autosom domin condit patient one healthi huntingtin gene one
mutant allel mhtt increas gag repeat lead progress huntingtin protein mis-fold
number gag repeat vari patient gag repeat earlier onset
allel wild type htt wild type huntingtin protein critic earli brain develop though
clear import normal huntingtin protein cognit function adult
mutant huntingtin gene fatal
believ hd caus increas toxic mhtt inadequ wild-typ level
could stabil improv hd progress lower level mhtt protein
believ key driver diseas patholog progress
shown lower mhtt protein csf potenti greater reduct
longer durat treatment
importantli allel specif mean knock wild type diseas
wild tabrizi
far know lower mhtt protein time csf show
mechan work hd patient intend target engag perspect
antisens deliveri challeng target engag show mhtt level
lower dose depend manner key mileston
phase studi result monthli dose show mean reduct mhtt
csf highest dose
translat mhtt reduct cortex caudat region brain base predict
mhtt continu declin last measur suggest potenti declin
howev think result cognit measur far earli conclus
view ultim key metric regul patient care
enter earli data on-going open label studi
think could first meaning read cognit endpoint hd program
far seen data month time point ole extens studi
think like earli see clinic benefit
roch commit updat ole dataset could updat cognit
endpoint updat
month analysi took place march durat data
biomark present may updat late june hdsa well potenti updat
meet late septemb md earli octob eha could venu get addit color
think next updat could key understand clinic implic lower mhtt
longer period time
importantli cognit data matter phase ole could form basi
acceler file us major stock focu
roch said plan discuss potenti file path regul later year presum
month endpoint ole studi
acceler file estim could acceler launch timelin year due size scale
phase program
think difficult handicap whether program file acceler approv
somewhat cautiou given riski develop space number outstand biolog question
coupl rel larg preval vs ole propos
cognit data limit far mhtt link diseas progress key question
much lower long show differ cognit endpoint
month associ degre mhtt lower cognit endpoint
improv seen
think hard draw conclus data potenti cognit data updat
much longer durat key catalyst program
degre mhtt lower correl improv score tm sdmt swrt
signific correl also note mhtt lower cuhdr one primari
ultim find data larg inconclus earli time point cognit standpoint
natur histori data think key refer point judg cognit trend
roch plan updat ole expect get potenti year dose data
focus effect fda requir endpoint cuhdr global requir
key comparison natur histori data think track hd studi could help
data point refer compar cognit progress treat patient
baselin think patient ole look similar earli hd cohort
mani outstand scientif question make challeng space pioneer
question unknown field
much lower mhtt need much lower mutant huntingtin mhtt lead
clinic meaning stabil cognitive/funct effect ionis/roch far
demonstr lower mhtt though expect declin time
long-term implic lower normal htt ionis/roch lower normal htt
mutant htt protein know long term implic lower normal htt protein
brain coverag distribut primarili cortex link cognit striatum
deeper brain less penetr also implic diseas loss motor function
cognit endpoint challeng lengthi show improv neurolog cognit
endpoint histor drug develop challeng show meaning benefit
patient variabl subject measur key consider
find right endpoint hd particular import
larg phase initi primari cognit endpoint month suggest
mani year studi read
note roche/ioni recent modified/restart march extend dose frequenc
base month analysi ole studi suggest everi month dose
achiev compar knockdown mhtt monthli dose
addit compani plan roll patient initi phase onto on-going ole studi
increas size dataset
updat everi
month
cuhdr phase primari endpoint look
datapoint close roch give cognit updat phase ole studi
ioni view cuhdr quantit sensit scale fda inform diseas progress
fda prefer sinc show patient abil perform daili task drive car
howev earli diseas high degre reduct
roch present ehdn
competit key factor show cognit benefit lower mhtt
essenti valid mhtt key biomark speed develop earlier stage player
success think highli like mani competitor also success
specif show mhtt lower lead cognit benefit and/or support
acceler file pave path mani program develop also lower
mani preclin clinic program develop huntington also
target either mhtt wild-typ htt like mhtt may superior long-
ioni roch current lead benefit could narrow
competit key factor close watch updat wve program
mani approach develop also lower mhtt
specif wave cover partner takeda cover allel specif target
mutant htt protein approach develop initi data guid
uniqur piro overweight gene therapi program develop guid enter phase
companyassettargetmodalitystag timelinesphas initi ole updat june preclincialmuhtt rna muhtt rna mu htt data mrnagen therapi mirna phase initi mrnarnai deliveri gene therapi preclinicalind file guid stagemuhtt gene repressiongen therapi zn finger nucleas preclinicalptctpreclin stagealtern splicingsmal protein tract mhttaav deliv intrabodypreclinicalneubas preclinicalhtt petide-nucl acid antisensepreclinicalexicurepreclinicalhttspher nucleic acidspreclinical-phas compani mrnaantisens april
tegsedi cautiou near-term due
drug profil competit think
next gener lica asset gain
think subq administr could drive uptak initi cautiou
around longer term adher tegsedi
ionis/akcea next gener ttr-lrx estim launch think could
key growth driver compani
long-term think ttr market larg commerci
ttr market new market recent therapeut approv alnylam
ionis/akcea alnylam ions/akcea first diseas modifi therapi
current alnylam ionis/akcea compet polyneuropathi market
roughli around patient diagnos market
pfizer tafamidi got complet respons letter jun approv europ
sold brand vyndaqel ttr stabil lower protein mg approv
expect approv hereditari cardiomyopathi wild-typ year
pdufa juli
report posit data attr-act look group march
reduct combin all-caus mortal frequenc cardiovascular-rel hospit
compar placebo month dose studi
expect approv polyneuropathi sinc wasnt studi
longer term competit could come eido develop therapi cardiomyopathi wild-
compani report cantor fitzgerald
descriptionapproved/expect approvalshereditari ttr polyneuropathi genet mutat result misfold ttr protein deposit nervesalnylam onpattroioni akcea tegsedipf vyndaqel eu polyneurpathi hereditari ttr cardiomyopathi genet mutat result misfold ttr protein deposit heart mostlypf tafamidi expect approv juli hereditari ttrsame caus patient deposit heart nervesno explicit label either approv therapi may use base symptomswild type ttr cardiac ttr amyloidosi similar famili attr amyloidosi except protein deposit normal non-mut transthyretin proteinpf tafamidi expect approv juli ttr market landscap investor debat tegsedi focu market opportun much share
tegsedi get market
near-term debat focus polyneuropathi tegsedi
long-term debat focus lica platform technolog uptak cardiomyopathi wild-typ
big hereditari
current tegsedi approv
along onpattro alnylam
ww patient diagnos
us coupl thousand eu
believ number reason
preval literatur
could potenti conserv
consist support
much diagnos
polyneuropathi patient
commer near-term
current diagnosi polyneuropathi low
often get question around
long take diagnos patient
come treatment sinc first
would expect diagnos
market treat next year
underway find patient
mutat usual exist
much share tegsedi
take polyneuropathi
alnylam onpattro approv
market near-term
tegsedi consensu
estim sale lower consensu
think tolerabl profil
tegsedi challeng though subq
appeal
market think onpattro
take major share tegsedi
number surpris see upsid
stock cours
big overal ttr
market think long-
term year
estim preval polyneuropathi
cardiomyopathi estim
wild-typ anoth patient
think market potenti
grow time
sever fatal diseas bullish
ioni alnylam
potent
overal size market long-term
next-gener ttr
agent penetr wild-typ
cardiac popul
like enter market
ionis/akcea alnylam
long-term estim newer lica
asset grow ions/akca share ttr
market think lica platform
significantli better safeti
implicit assumpt
think ttr lower
therapi potent
stabil expect
tegsedi bullish lica well
compani strong data
estim launch
cardiac wild-typ
compani report cantor fitzgerald
ttr view summar think market suffici big bullish lica long-
term platform near-term opportun tegsedi
think ttr market larg untap market opportun biotech
estim polyneuropathi could base preval
think market potenti grow time sever fatal diseas
ad cardiomyopathi wild-typ patient
think diagnos polyneuropathi patient like treat year
key question mani mix phenotyp patient treat
near-term estim tegsedi take market longer term lica gain
market vs tafamidi product
think patient may start tegsedi think toler may increas discontinu time
estim alnylam take major polyneuropathi market
long-term think ionis/akeca lica platform take greater share due potenc
safeti also access bigger market like cardiomyopathi wild-typ
therefor base case still get peak sale
alnylam also develop therapi well think market big
notabl think bigger lica drug may factor valuat base model
base view consensu next year polyneuropathi
note ions/akca abl beat expect near-term key risk neutral
attr amyloidosi sever life threaten diseas think larg
demand treatment tegsedi correct diseas
attr amyloid transthyretin diseas caus protein transthyretin becom unstabl
prone aggreg
transthyretin aggreg result amyloid deposit larg clump fold protein
progress accumul bodi nerv and/or heart lead fatal damag
amyloid deposit driver symptom patholog diseas
accumul nerv progress damag muscl lead wast away
accumul heart progress damag heart lead heart failur
wide rang phenotyp genotyp attr stem
root caus misfold ttr protein
depend ttr amyloid fibril deposit symptom patholog diseas
polyneuropathi neurolog present progress muscl weak weight loss loss feel
eventu death muscl deterior failur autonom nervou system
cardiomyopathi present often asymptomat thicken heart due deposit caus declin
cardiac function symptom similar heart failur patient short breath palpit
wide rang present symptom attr made complic diagnosi
tegsedi onpattro correct root caus attr silenc product ttr
protein think work regardless genotyp phenotyp
tegsedi onpattro lower ttr level averag
treatment bind ttr mrna prevent translat ttr protein
result ttr product block prevent format ttr amyloid deposit
alnylam use sirna double-strand vs ioni approach use antisens singl strand
mechan action prevent ttr product block ttr mrna nearli ident
tegsedi onpattro recent approv hereditari polyneuropathi variant
attr show strong data neuropathi outcom measur
alnylam onpattro ionis/akcea tegsedi approv fda august octob
respect hereditari polyneuropathi form attr
drug shown clear strong improv neuropathi
improv neuropathi symptom diseas measur mni scale
baselin comparison vari includ primari efficaci illustr
market size ttr opportun
think polyneuropathi mix phenotyp big polyneuropathi mix
phenotyp patient treat market size
patient global hereditari ttr neuropathi symptom current label
addit estim patient non-hereditari ttr cardiac symptom
see growth potenti longer term
patient hereditari attr neuropathi sever present symptom
progress muscl weak nerv dysfunct pain numb
current cost net price polyneuropathi therapi
wild type ttr peripher neuropathi mix neuro cardio cardiomyopathi hereditari ttr world-wide ttr patient typewild type ttrperipher neuropathymix neuro cardiocardiomyopathi market size ttr opportun
think hereditari ttr could grow market opportun half
patient diagnos treat
think hereditari ttr signific potenti meaning orphan diseas opportun
given sever diseas think major patient diagnos treat
depend identif penetr patient mix neuropathi phenotyp even
penetr genet cardiomyopathi patient see signific sale potenti initi
highlight sensit
symptomsonli mix phenotyp cardiomyopathyhereditari ttr potenti market size diagnosi neuropathi symptom mix phenotyp cardiomyopathytot address patient rateannu net pricetot market diagnosi preval polyneuropathi patient
howev diagnosi larg swing factor key move piec larg market
opportun near long term
ionis/akcea alnylam describ current diagnosi rate hereditari attr
given rariti complex diseas varieti way present think patient
physician educ key note compani make progress front
diagnos mani patient
check newli diagnos patient asymptomat may less inclin receiv
treatment near-term
anoth swing factor proport diagnos symptom neuropathi
current label indic
howev expect time given better treatment avail diagnosi rate
check suggest mani physician prefer onpattro tolerablilti profil see
usag tegsedi easier subq administr prefer
key advantag tegsedi onpattro conveni sub-q administr vs onpattro
requir minut iv infus although at-hom administr option
howev tegsedi signific monitor requir monitor advers event
monitor typic done home requir continu surveil
clinic studi case renal failur life-threaten thrombocytopenia low
platelet link tegsedi treatment think experi like commerci could discourag
usag physician
onpattrotegsedicompanyalnylamionisu approvalaugust hereditari ttr polyneuropathi hereditari ttr administrationiv subqfrequencyeveri weeksweeklyinfus warningsnonethrombocytopeniaglomberulonephritisrequir rem programnoneyesplatelet monitor creatinin egfr upcr noneeveri weeksliv testsnoneeveri frequent platelet level per fda label onpattro administ iv minut assum subq home take minutessourc compani data fda label cantor fitzgerald equiti research frame long-term opportun
hereditari attr symptom present along spectrum neuropathi cardiomyopathi
think tegsedi onpattro potenti use popul
diseas present ttr amyloid fibril deposit often driven specif
mutat caus diseas
dozen genet mutat link ttr
howev underli caus mutat ttr across patient
frame long-term opportun
long-term think market opportun ttr rna knockdown agent signific
growth potenti expans cardiac wild-typ non-genet form ttr
current indic genet neuropathi phenotyp ttr patient popul
cardiac wild-typ non-genet form diseas much larger
think ttr knockdown agent signific potenti cardiac wild-typ popul
outcom data take time gener
plan start phase studi popul next-gener ttr agent later
pfizer tafamidi oral ttr stabil upcom pdufa wild-typ cardiac
onpattro
longer term
studi
ttrwild type ttrtotal ttr patientsttr patient populationneuropathi symptomscardiomyopathi frame long-term opportun
think next gener agent alni vitusiran ions/akca ttr-lrx significantli
expand attr market
longer term studi design gener data cardiovascular outcom
think agent mechanist perform better tafamidi base mechan
check longer term safeti data import cardiologist get comfort use
rna-bas therapi larger popul
frame long-term opportun
also think ttr-lrx help level competit play field earli
ionis/akcea rel alnylam
think efficaci toler two next gener product look
similar first gener product could improv ionis/akcea commerci stand
current think side effect tegsedi may disadvantag product commerci
alnylam start phase vutrisiran polyneuropathi earli ionis/akcea plan
initi phase studi ttr-lrx polyneuropathi
think time market import factor gain share track
advantag tegsedi onpattro subq vs iv alnylam next gener product
subq ionis/akcea timelin market next gener import competit
hattr polyneuropathyalni vutrisiran ions/akca ttr-lrxlengthstudyhelios-aphas enrol startjanuari enrol completel month readoutmid month primaryfil mid month frame long-term opportun
although posit lica platform also note alnylam eido drug
develop cardiomyopathi wild-typ compet well
expect initi larger scale cardiomyopathy/wild-typ ttr studi later year
updat enrol trial length help think time market next
overview addit ttr studi plan underway
companystudyphasepopulationdrugtimingcantor estim readout hereditari cardiomyopathyonpattrostart mwd polyneuropathyvutrisiraniniti earli norfolk hereditari cardiomyopathyvutrisiranguid start late yet announc tafamidi primari polyneuropathyttr-lrxguid start yet hereditari cardiomyopathyttr-lrxguid start polyneuropathi yet announc april
take tegsedi think overal ttr market size underappreci longer term
cautiou near-term tegsedi number
long term bullish ttr opportun ttr-lrx ions/akca vutrisiran
think market larger investor appreci
long-term think hereditari ttr alon grow larg market
potenti expans cardiac wild-typ ttr could doubl opportun
think ions/acka next gener product ttr-lrx could help level competit play field
near term cautiou tegsedi launch number due alnylam competit time diseas
awar increas
launch may slow initi diagnosi awar grow
current diagnosi rate due complex heterogen diseas expect grow
time
initi think ioni face steep competit
cautiou tegsedi uptak base comparison profil alni onpattro
driver ex-u sale
slightli consensu near-term due product side effect
profil think product could grow time
take waylivra think near-term sale expect look littl high think
product could grow time
toler larg question high discontinu case thrombocytopenia clinic
check suggest subset patient highli respons adher waylivra
option second indic fpl phase data add addit growth potenti
product
famili chylomicronemia syndrom fc rare lipid disord affect patient
world-wide estim
famili chylomicronemia syndrom fc patient lack enzym lipoprotein lipas lpl
essenti break triglycerid
result fc patient extrem high triglycerid level come host medic
triglycerid accumul form chylomicron block blood flow pancrea lead
acut pancreat key concern caus complic fc patient
reduc pancreat key treatment goal fc seriou acut complic diseas
waylivra show impress triglycerid lower like lower key diseas metric
 pancreat fda concern around safeti result
triglycerid elev link root caus fc diseas believ
triglycerid lower time could provid meaning benefit patient toler
reduct month reduct month lower due high discontinu rate
think fda reconsid waylivra provid path forward would posit surpris
think base review data profil possibl remain key unknown
waylivra approv eu posit chmp opinion march near-term eu launch updat
inform product potenti
side effect discontinu could limit uptak check suggest high patient
willing tri waylivra adjust advers event
waylivra sale vs consensu conserv learn
commerci profil waylivra
due side effect low diagnosi rate cautiou around uptak waylivra
patient persist higher diagnosi faster and/or waylivra approv us fc eu
and/or us second indic pfl data guid could drive upsid
financi model valuat
commerci revenu product sale product commerci revenu revenu revenu revenu total revenu opex incom oper margin tax expens tax loss/incom loss non-controlling interest akcea net loss/incom basic ep ep weight average weight average balanc sheet
sheetasset cash equival short-term current plant equip stockhold equiti current portion defer contract convert senior oblig less current defer contract ioni stockhold interest akcea stockhold liabil stockhold manag background
chairman board chief execut offic
dr crook founder chairman chief execut offic leadership ioni pioneer
develop revolutionari antisens technolog platform creat one largest advanc pipelin
biotechnolog industri today ioni medicin develop includ four enter pivot studi
larger number phase clinic studi
chief oper offic senior vice presid translat medicin
dr monia found member ioni chief oper offic senior vice presid translat medicin march
appoint ioni board director contribut includ research medicin chemistri mechan
action oligonucleotide-bas drug cell cultur anim establish numer preclin clinic program
mani result clinic proof concept variou therapeut area includ oncolog metabol diseas inflamm
cardiovascular diseas rare diseas
dr bennett senior vice presid research respons preclin antisens drug discoveri
antisens technolog research dr bennett also franchis leader neurolog program ioni one found
member compani dr bennett involv develop antisens oligonucleotid therapeut agent includ
research applic oligonucleotid inflammatori neurodegen diseas cancer oligonucleotid deliveri
pharmacokinet medicin chemistri dr bennett publish paper field antisens research
develop issu patent
senior vice presid financ chief offic
ms hougen senior vice presid financ chief offic respons overse
oper financ account inform technolog facil purchas ms hougen join ioni may
ioni platform technolog compani base antisens rna approach compani power drug discoveri engin
asset clinic develop
